Elevated circulating follistatin associates with an increased risk of type 2 diabetes
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The hepatokine follistatin is elevated in patients with type 2 diabetes (T2D) and promotes hyperglycemia in mice. Here we explore the relationship of plasma follistatin levels with incident T2D and mechanisms involved. Adjusted hazard ratio (HR) per standard deviation (SD) increase in follistatin levels for T2D is 1.24 (CI: 1.04–1.47, p < 0.05) during 19-year follow-up (n = 4060, Sweden); and 1.31 (CI: 1.09–1.58, p < 0.01) during 4-year follow-up (n = 883, Finland). High circulating follistatin associates with adipose tissue insulin resistance and non-alcoholic fatty liver disease (n = 210, Germany). In human adipocytes, follistatin dose-dependently increases free fatty acid release. In genome-wide association study (GWAS), variation in the glucokinase regulatory protein gene (GCKR) associates with plasma follistatin levels (n = 4239, Sweden; n = 885, UK, Italy and Sweden) and GCKR regulates follistatin secretion in hepatocytes in vitro. Our findings suggest that GCKR regulates follistatin secretion and that elevated circulating follistatin associates with an increased risk of T2D by inducing adipose tissue insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Assarsson, E., Lundberg, M., Holmquist, G., Björkesten, J., Bucht Thorsen, S., Ekman, D., Eriksson, A., Rennel Dickens, E., Ohlsson, S., Edfeldt, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095192 · Cited by 1,874
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
A deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans
Stefan, N., Schick, F., & Häring, H.-U. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.008 · Cited by 575
Self-citationBiology of upper-body and lower-body adipose tissue—link to whole-body phenotypes.
Karpe, F., & Pinnick, K. E. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.185 · Cited by 543
Beer, N. L., Tribble, N. D., McCulloch, L. J., Roos, C., Johnson, P. R. V., Orho-Melander, M., & Gloyn, A. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp357 · Cited by 401
Self-citationMolecular Physiology of Mammalian Glucokinase
Iynedjian, P. B. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8322-9 · Cited by 365
Quadrupling Muscle Mass in Mice by Targeting TGF-ß Signaling Pathways
Lee, S.-J. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000789 · Cited by 316
Research works printed but not linked: 19
- Jones, K. L. et al. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc. Natl Acad. Sci. USA 104, 16239–16244 (2007). · DOI · Paper page
- Medeiros, E. F., Phelps, M. P., Fuentes, F. D. & Bradley, T. M. Overexpression of follistatin in trout stimulates increased muscling. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297, R235–R242 (2009). · DOI · Paper page
- Nakamura, T. et al. Activin-binding protein from rat ovary is follistatin. Science 247, 836–838 (1990). · DOI · Paper page
- Zimmers, T. A. et al. Induction of cachexia in mice by systemically administered myostatin. Science 296, 1486–1488 (2002). · DOI · Paper page
- Zhao, C. et al. Overcoming Insulin Insufficiency by Forced Follistatin Expression in beta-cells of db/db Mice. Mol. Ther. 23, 866–874 (2015). · DOI · Paper page
- Orho-Melander, M. et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57, 3112–3121 (2008). · DOI · Paper page
- Borne, Y. et al. Complement C3 Associates With Incidence of Diabetes, but No Evidence of a Causal Relationship. J. Clin. Endocrinol. Metab. 102, 4477–4485 (2017). · DOI
- Rees, M. G. et al. Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 55, 114–122 (2012). · DOI · Paper page
- Lopez, M. Rodriguez et al., Identification and characterization of a FOXA2-regulated transcriptional enhancer at a type 2 diabetes intronic locus that controls GCKR expression in liver cells. Genome Med 9, 63 (2017). · DOI
- Lloyd, D. J. et al. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors.Nature 504, 437–440 (2013). · DOI
- Staehr, P. et al. Effects of free fatty acids per se on glucose production, gluconeogenesis, and glycogenolysis. Diabetes. 52, 260–267 (2003). · DOI · Paper page
- Sakamoto, Y. et al. Determination of free follistatin levels in sera of normal subjects and patients with various diseases. Eur J Endocrinol. 135, 345–351 (1996). · DOI
- Vamvini, M. T., Aronis, K. N., Chamberland, J. P. & Mantzoros, C. S. Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males. J Clin Endocrinol Metab. 96, 3416–3426 (2011). · DOI · Paper page
- Grimsby, J. et al. Characterization of glucokinase regulatory protein-deficient mice. J Biol Chem. 275, 7826–7831 (2000). · DOI · Paper page
- Jin, L. et al. Role of glucokinase in the subcellular localization of glucokinase regulatory protein. Int J Mol Sci. 16, 7377–7393 (2015). · DOI
- Farrelly, D. et al. Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation. Proc Natl Acad Sci USA. 96, 14511–14516 (1999). · DOI · Paper page
- Brouwers, M., Jacobs, C., Bast, A., Stehouwer, C. D. A. & Schaper, N. C. Modulation of glucokinase regulatory protein: A double-edged sword? Trends Mol Med. 21, 583–594 (2015). · DOI
- Mattisson, I. Y. et al. Elevated markers of death receptor-activated apoptosis are associated with increased risk for development of diabetes and cardiovascular disease. EBioMedicine. 26, 187–197 (2017). · DOI
- Bao, X. et al. Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmo Diet and Cancer-Cardiovascular Cohort. Diabetologia. 62, 78–86 (2019). · DOI · Paper page
Cited by
The role of hepatokines in NAFLD
Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H.-U., & White, M. F. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.006 · Cited by 282
Self-citationInter-organ crosstalk during development and progression of type 2 diabetes mellitus
Xourafa, G., Korbmacher, M., & Roden, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00898-1 · Cited by 274
“In NAFLD, circulating hepatokines (such as follistatin, fetuin A and fetuin B) are associated with an increased risk of T2DM, possibly via inducing peripheral insulin resistance 156,246,247 or pleiotropic effects 149,152,184,248–250 .”
BackgroundStefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Bone-muscle crosstalk under physiological and pathological conditions
Dong, Y., Yuan, H., Ma, G., & Cao, H. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05331-y · Cited by 52
“Inhibition of myostatin can lead to reduced AT and strengthened bones and muscles [95], but the direct roles of myostatin on bones is still unknown.”
Background
Metadata
- Authors
- Wu, C., Borné, Y., Gao, R., López Rodriguez, M., Roell, W. C., Wilson, J. M., Regmi, A., Luan, C., Aly, D. M., Peter, A., Machann, J., Staiger, H., Fritsche, A., Birkenfeld, A. L., Tao, R., Wagner, R., Canouil, M., Hong, M.-G., Schwenk, J. M., Ahlqvist, E., Kaikkonen, M. U., Nilsson, P., Shore, A. C., Khan, F., Natali, A., Melander, O., Orho-Melander, M., Nilsson, J., Häring, H.-U., Renström, E., Wollheim, C. B., Engström, G., Weng, J., Pearson, E. R., Franks, P. W., White, M. F., Duffin, K. L., Vaag, A. A., Laakso, M., Stefan, N., Groop, L., & De Marinis, Y.
- Venue
- Nature Communications
- Published
- 2021-11-10
- Volume
- 12
- Issue
- 1
- Pages
- 6486-6486
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W3213389536
- Cited by
- 67
- References
- 17
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- Vetenskapsrådet (2009-1039)
- Stiftelsen för Strategisk Forskning (IRC15-0067)
- European Foundation for the Study of Diabetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elevated circulating follistatin associates with an increased risk of type 2 diabetes. https://app.cochat.ai/papers/10.1038/s41467-021-26536-w
- The paper
- Wu, C., Borné, Y., Gao, R., López Rodriguez, M., Roell, W. C., Wilson, J. M., Regmi, A., Luan, C., Aly, D. M., Peter, A., Machann, J., Staiger, H., Fritsche, A., Birkenfeld, A. L., Tao, R., Wagner, R., Canouil, M., Hong, M.-G., Schwenk, J. M., . . . De Marinis, Y. (2021). Elevated circulating follistatin associates with an increased risk of type 2 diabetes. Nature Communications. https://doi.org/10.1038/s41467-021-26536-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.